跳至主要内容
临床试验/NCT04224064
NCT04224064招募中不适用

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

Institut du Cancer de Montpellier - Val d'Aurelle2 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2020年8月26日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
158
试验地点
2
主要终点
Sensibility and specificity of circulating serine level for LPS diagnosis

研究概览

简要总结

The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.

详细描述

Sarcomas are rare diseases, accounting for less than 1% of all malignant diseases in adults¹. Their incidence is about 6 new cases per 100,000 in inhabitants per year, ie 4,000 to 5,000 new cases estimated per year in France.

Liposarcoma (LPS) is the most common soft tissue sarcoma subtype, accounting for approximately 15% of all sarcomas.

The OMS classification distinguishes 5 categories of LPS: myxoid, pleomorphe, round-cell liposarcomas, dedifferentiated (DD-LPS) and well-differentiated (WD-LPS). Research team is interested by the last two in this study.

The diagnosis is suspected on the imaging examinations (MRI for limb tumors and CT for retro-peritoneal LPS) which should lead to a discussion at a multidisciplinary tumor board in an expert center to validate the biopsy for definitive diagnosis and define the best biopsy route to avoid the risk of spread. In France, the management of patients with sarcoma is organized around the network of 24 "NETSARC" centers.

WD-LPS and DD-LPS, may be difficult to distinguish from benign adipose tumors and undifferentiated sarcomas, respectively. Molecular analyze, based on the detection of Mdm2 gene amplification by Fluorescence in situ Hybridization (FISH) is currently the "gold standard". It is performed on a tumor biopsy. The biopsy is a radiologic biopsy as it is recommended in the guidelines to reduce the risk of disease spread. The material allowing the diagnosis is thus limited complicating the realization of morphology, immunohistochemistry and molecular biology on the same sample. The other limitation is that this tumor fragment does not always reflect intra-tumor heterogeneity.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • for LPS patients cohort:
  • Men/women older than 18 years old,
  • Surgery for :
  • Localized WD-LPS and DD-LPS, and/or
  • WD-LPS or DD-LPS local relapse, and/or
  • WD-LPS or DD-LPS distant relapse and/or
  • Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent
  • Inclusion Criteria for healthy subjects cohort:
  • Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort

排除标准

  • Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.
  • Pregnancy and/or feeding

结局指标

主要结局

Sensibility and specificity of circulating serine level for LPS diagnosis

时间窗: At 3 months post surgery

Circulating serine level is a quantitative variable evaluated by its concentration

次要结局

  • Difference in circulating serine level(18 months after surgery)
  • Relapse-free survival (RFS)(Until the study completion: 2 years)

研究者

发起方
Institut du Cancer de Montpellier - Val d'Aurelle
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Identification of a New Blood Biomarker for the... | 临床试验